Apyx (APYX) delivered earnings and revenue surprises of 72.73% and -5.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
PHILADELPHIA, PA / ACCESSWIRE / April 20, 2020 / Kaskela Law LLC is investigating Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ:APYX) on behalf of the Company's investors. ...
LOS ANGELES, CA / ACCESSWIRE / April 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.
As of late, it has definitely been a great time to be an investor of Apyx Medical
Apyx (APYX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Kaskela Law LLC is investigating Apyx Medical Corporation (NASDAQ: APYX) ("Apyx" or the "Company") on behalf of the Company’s stockholders.
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today announced that financial results for the first quarter of fiscal year 2020 will be released before the market opens on Monday, May 11.
NEW YORK, May 15, 2020 -- Advance Auto Parts, Inc. (AAP) Lifshitz Law Firm announces investigation into possible breaches of fiduciary duty by certain of Advance Auto Parts’.
Advance Auto Parts, Inc. (AAP)
Shares of Apyx Medical (NASDAQ:APYX) were flat in pre-market trading after the company reported Q1 results.Quarterly Results Earnings per share fell 42.86% over the past year to ($0.20), which beat the estimate of ($0.25).Revenue of $4,997,000 less by 14.19% year over year, which missed the estimate of $5,200,000.Outlook Apyx Medical hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.Details Of The Call Date: May 11, 2020View more earnings on APYXTime: 08:01 PM ETWebcast URL: https://78449.themediaframe.com/dataconf/productusers/apyx/mediaframe/36949/indexl.htmlRecent Stock Performance Company's 52-week high was at $8.5952-week low: $2.81Price action over last quarter: down 24.31%Company Profile Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. The company's product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons and cosmetic physicians a unique ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives majority revenue.See more from Benzinga * Recap: Contura Energy Q1 Earnings * Recap: Vuzix Q1 Earnings * Recap: WAVE Life Sciences Q1 Earnings(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
LOS ANGELES, CA / ACCESSWIRE / March 31, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.
Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Apyx Medical Corporation (NASDAQ: APYX) resulting from allegations that Apyx may have issued materially misleading business information to the investing public.
Schubert Jonckheer & Kolbe LLP is investigating potential shareholder derivative claims on behalf of stockholders of Apyx Medical Corporation (NASDAQ: APYX) related to the company's statements regarding its December 2018 application to the U.S. Food and Drug Administration for expanded uses of Apyx's J-Plasma technology—the company's key growth product.
Johnson Fistel, LLP is investigating potential claims on behalf of Apyx Medical Corporation (formerly Bovie Medical) ("Apyx" or the "Company") (APYX) against certain of its officers and directors. In 2019, a Securities Class Action Complaint was filed on behalf of those who purchased securities of Apyx between August 1, 2018 through April 1, 2019. According to the lawsuit, defendants throughout the Class Period made false and misleading statements and failed to disclose that: (1) the clinical study on the use of J-Plasma, a plasma-based surgical product for cutting, coagulation, and ablation of soft tissue, for dermal resurfacing had not met its primary efficacy endpoint; (2) the clinical study did not support Apyx's application for regulatory clearance; (3) Apyx was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants' positive statements about Apyx's business, operations, and prospects were materially false and misleading and lacked a reasonable basis.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or "the Company") (NASDAQ:APYX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Apyx admitted on March 16, 2020, that its financial results for multiple periods, including the 12 months ending December 31, 2019, the quarterly statements for the three and nine-months periods ending September 30, 2018, and the three months ending March 31, 2019, could no longer be considered reliable and would require restating.
On April 17, 2019, a lawsuit was filed against Apyx Medical Corporation /k/a/ Bovie Medical Corporation over alleged Securities Laws Violations. The plaintiff alleges that the Defendants made false and/or misleading statements and/or failed to disclose that the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint, that, as a result, the clinical study did not support the Company’s application for regulatory clearance, that, as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing, and that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis. On September 3, 2019, an amended complaint was filed, and on October 3, 2019, the defendants filed their motion to dismiss the case.
Pomerantz LLP is investigating claims on behalf of investors of Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, today reported financial results for its first quarter ended March 31, 2020.
Image source: The Motley Fool. Apyx Medical Corp (NASDAQ: APYX)Q1 2020 Earnings CallMay 11, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: OperatorGood morning, ladies and gentlemen, and welcome to the first quarter fiscal-year 2020 earnings call for Apyx Medical Corporation [Operator instructions].
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Apyx Medical Corporation (NasdaqGS: APYX).